When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Ovarian cancer

Last reviewed: 11 Dec 2025
Last updated: 12 Mar 2025

Summary

Definition

History and exam

Key diagnostic factors

  • pelvic mass
  • ascites
  • pleural effusion
Full details

Other diagnostic factors

  • gastrointestinal symptoms
  • urinary urgency or frequency
  • symptom duration >3 months
  • abdominal distention
  • pelvic/abdominal pain or pressure
Full details

Risk factors

  • genetic mutations associated with hereditary ovarian cancer
  • increasing age
  • family history of ovarian cancer, breast cancer, colorectal cancer, and/or endometrial cancer
  • never used combined oral contraceptives
  • nulliparity
  • obesity
  • hormone therapy
  • endometriosis
Full details

Diagnostic tests

1st tests to order

  • pelvic ultrasound
  • CA-125
  • histopathology
Full details

Tests to consider

  • genetic testing
  • PET, PET-CT, or PET/MRI
  • MRI
  • CT scan
  • biomarker tests
Full details

Treatment algorithm

ACUTE

surgical candidate, intraoperative histology confirmed disease

poor surgical candidate, biopsy confirmed disease

ONGOING

platinum-sensitive recurrent disease

platinum-resistant recurrent or refractory disease

Contributors

Authors

Sareena Singh, MD

Gynecologic Oncologist

Aultman Medical Group

Northeast Ohio Medical University

Canton

OH

Declarações

SS declares that she has no competing interests.

Agradecimentos

Dr Sareena Singh would like to gratefully acknowledge Dr Justin C. Chura and Dr Allison E. Axtell, previous contributors to this topic.

Declarações

JCC and AEA declare that they have no competing interests.

Revisores

Michael P. Hopkins, MD, MEd

Chairman

Obstetrics and Gynecology

Northeast Ohio Universities of Medicine (NEOMED)

Rootstown

OH

Declarações

MPH declares that he has no competing interests.

Ritu Salani, MD

Gynecologic Oncology Fellow

Johns Hopkins Medical Institutions

Baltimore

MD

Declarações

RS declares that she has no competing interests.

Susan A. Davidson, MD

Associate Professor

Chief, Gynecologic Oncology

Department of Obstetrics & Gynecology (UCD)

University of Colorado Cancer Center

Aurora

CO

Declarações

SAD declares that she has no competing interests.

Khadra Galaal, MBChB, MPH, MRCOG

Consultant Gynaecological Oncologist

Northern Gynaecological Oncology Centre

Queen Elizabeth Hospital

Gateshead

UK

Declarações

KG is co-author of a systematic review of follow-up strategies after primary treatment in ovarian cancer. This is not referenced in this topic.

Jill Tseng, MD

Assistant Clinical Professor of Gynecologic Oncology

University of California, Irvine

Orange

CA

Declarações

JT declares that she has no competing interests.

Créditos aos pareceristas

Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.

Declarações

As afiliações e declarações dos pareceristas referem--se ao momento da revisão.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer [internet publication].Texto completo

González-Martín A, Harter P, Leary A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Oct;34(10):833-48.Texto completo  Resumo

Gaillard S, Lacchetti C, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update. J Clin Oncol. 2025 Mar;43(7):868-91.Texto completo  Resumo

Berek JS, Renz M, Kehoe S, et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):61-85.Texto completo  Resumo

Tew WP, Lacchetti C, Kohn EC, et al. Poly(ADP-Ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022 Nov 20;40(33):3878-81.Texto completo  Resumo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
  • Ovarian cancer images
  • Diagnósticos diferenciais

    • Irritable bowel syndrome (IBS)
    • Metastases to the ovary
    • Endometriosis
    Mais Diagnósticos diferenciais
  • Diretrizes

    • Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update
    • Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment
    Mais Diretrizes
  • Folhetos informativos para os pacientes

    Ovarian cancer: what is it?

    Ovarian cancer: what are the treatment options?

    Mais Folhetos informativos para os pacientes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal